- Home
- WATT vs IBIO Comparison
WATT vs IBIO Comparison
Compare WATT & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- IBIO
- Stock Information
- Founded
- WATT 2012
- IBIO 2008
- Country
- WATT United States
- IBIO United States
- Employees
- WATT N/A
- IBIO N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- IBIO Health Care
- Exchange
- WATT Nasdaq
- IBIO Nasdaq
- Market Cap
- WATT 9.1M
- IBIO 9.3M
- IPO Year
- WATT 2014
- IBIO N/A
- Fundamental
- Price
- WATT $0.28
- IBIO $0.77
- Analyst Decision
- WATT
- IBIO Strong Buy
- Analyst Count
- WATT 0
- IBIO 3
- Target Price
- WATT N/A
- IBIO $4.87
- AVG Volume (30 Days)
- WATT 2.0M
- IBIO 776.1K
- Earning Date
- WATT 05-13-2025
- IBIO 05-02-2025
- Dividend Yield
- WATT N/A
- IBIO N/A
- EPS Growth
- WATT N/A
- IBIO N/A
- EPS
- WATT N/A
- IBIO N/A
- Revenue
- WATT $1,047,000.00
- IBIO $375,000.00
- Revenue This Year
- WATT $1,028.91
- IBIO $36.00
- Revenue Next Year
- WATT N/A
- IBIO N/A
- P/E Ratio
- WATT N/A
- IBIO N/A
- Revenue Growth
- WATT 137.41
- IBIO 650.00
- 52 Week Low
- WATT $0.12
- IBIO $0.64
- 52 Week High
- WATT $2.70
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- WATT 50.45
- IBIO 30.08
- Support Level
- WATT $0.27
- IBIO $0.70
- Resistance Level
- WATT $0.29
- IBIO $0.83
- Average True Range (ATR)
- WATT 0.02
- IBIO 0.06
- MACD
- WATT 0.00
- IBIO 0.08
- Stochastic Oscillator
- WATT 40.25
- IBIO 41.18
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.